Automated vitrification in IVF labs: what Gavi, DaVitri and the trials actually show
Published 26 October 2026 · IVF Automation · Lab operations
Vitrification is one of the most hands-on, skill-dependent steps in an embryology lab, and the first machines built to automate it have now been tested in real clinics. The headline from those trials is not "the robot beats the embryologist". It is more useful than that: semi-automated systems can match a skilled manual method, but they change time, workflow and training in ways a lab manager has to plan for.
This guide summarises what the published evidence says about two semi-automated vitrification systems, what it does not say, and the questions an Indian lab should ask before buying.
Why vitrification is an automation target
Vitrification depends on moving oocytes or embryos through cryoprotectant solutions with tight timing, then cooling them very fast. The original 2014 Human Reproduction paper describing the Gavi system put the problem plainly: vitrification is "a manual, labour-intensive and highly skilled procedure, and results can vary between embryologists and clinics." The same paper notes that a closed system, where the sample does not touch liquid nitrogen directly, is preferred by many clinics and is a regulatory requirement in some countries.
That combination of operator variability, staff time and closed-system preference is exactly what automation vendors are targeting.
Gavi: from bench study to a randomised trial
What it does. The Gavi system, developed by Genea, automatically performs the equilibration steps before closed-system vitrification, on up to four embryos at a time.
The 2014 bench study. Using mouse embryos and a small number of donated human blastocysts (23 Gavi, 13 Cryotop controls), the developers reported in vitro outcomes equivalent to the manual Cryotop method, with 100% recovery in both human groups. The authors themselves flagged the limits: few human embryos, no pregnancy data, and funding and shareholdings tied to Genea and its engineering partner.
The 2021 randomised trial. Three German IVF centres ran a prospective, randomised non-inferiority trial (registered as NCT03287479) comparing Gavi with manual open Cryotop vitrification of pronuclear-stage oocytes. With 149 patients randomised and 118 in the per-protocol analysis, survival at warming was 94.0% with Gavi and 96.7% with Cryotop, meeting the trial's non-inferiority margin. Embryo development, pregnancy and live birth rates were described as similar.
The operational findings matter just as much:
- Mean total procedure time (vitrification plus warming) was 81 minutes with Gavi versus 47 minutes manually, a mean difference of 34 minutes.
- Staff convenience, rated by eight operators, was lower for Gavi, and most preferred Cryotop "because of practicality issues".
- The authors noted the centres had long manual-vitrification experience, and that Gavi's relative value may be higher where manual skill is lower. Costs were not measured.
DaVitri: microfluidic automation for oocytes
What it does. Overture Life's DaVitri system pairs a touch-screen station with a disposable microfluidic dish. A microfluidic pump moves reagents to and from the dish holding the oocytes, according to the trial registration (NCT06853418). The design keeps oocytes stationary during fluid exchange and uses an open well for retrieval.
The ESHRE 2025 abstract. A blinded, multicentre prospective study presented at ESHRE 2025 (abstract O-240) split 558 donor oocytes from 37 donors equally between DaVitri and manual vitrification across three IVF centres. Survival after warming was 79.6% with DaVitri and 84.2% manually; fertilisation was 74% in both groups; blastulation was 64.4% versus 56%. The authors reported non-inferiority across survival, fertilisation, blastulation and morphology.
Two cautions. First, this is a conference abstract on donor oocytes only, and the authors say a larger dataset is needed. Second, a pregnancy-outcomes study (NCT06853418, 260 planned participants) was still listed as recruiting at a single US site when last updated in the registry. Lab and laboratory-level results are not the same as pregnancy outcomes, and none of this predicts results for any individual patient.
What the evidence does and does not support
- Supported: semi-automated systems can reach survival and development figures comparable to skilled manual vitrification in the settings studied.
- Not yet shown: that automation improves clinical outcomes over a well-run manual programme, or that it saves time. In the one randomised trial, it took longer.
- The real promise: standardisation. Reducing operator-to-operator variability is the argument both developers make, and it is the one worth testing in your own lab.
Measure first: use the Alpha cryopreservation KPIs
Before deciding whether automation helps, a lab needs its own baseline. The Alpha consensus on cryopreservation KPIs (2012) defined 14 indicators with competency and benchmark values. For example, for oocyte vitrification it set morphological survival competency at 70% and the benchmark at 85% (95% for donors under 30). Alpha made no recommendation about specific devices or techniques.
A practical approach is to track survival per embryologist and per month in your lab data system or QC logs. If one operator or shift sits consistently below the others, that is the problem automation claims to solve. If everyone already performs near the benchmark, the business case rests on staffing and training rather than outcomes.
A buyer's checklist for Indian labs
- Ask for peer-reviewed data, not brochures. Ask which studies used the exact model and consumables you would buy, and who funded them.
- Check regulatory status in India. Ask the vendor or distributor for its CDSCO medical device registration or import licence for the instrument and consumables. See our guide to FDA and CDSCO status.
- Model the time cost. Use the 34-minute difference from the randomised trial as a planning question: how does the system fit your peak retrieval days?
- Price the consumables. Per-case disposable cost, supply lead time and local stock matter more than the capital price over a few years.
- Plan a validation run. Agree a side-by-side internal validation against your own Alpha KPIs before switching any clinical work.
- Connect it to witnessing and records. Confirm the device fits your witnessing and sample ID process. Records must also meet the ART Act 2021: Section 23(c) requires them to be kept for at least ten years (see our ART Act checklist).
- Think beyond the bench. Vitrification is only half of the cryo chain. Pair it with automated tank monitoring and ask the vendor about AMC and service terms.
The bottom line
Automated vitrification is real, published and in clinical trials, but it is early. Today the strongest case for it is consistency and closed-system handling, not speed or better results. Labs that already measure survival per operator will know quickly whether it solves a problem they actually have.
Sources
- Roy TK et al., Embryo vitrification using a novel semi-automated closed system yields in vitro outcomes equivalent to the manual Cryotop method, Human Reproduction, 2014
- A randomised, multi-center, open trial comparing a semi-automated closed vitrification system with a manual open system in women undergoing IVF, Human Reproduction, 2021
- ClinicalTrials.gov NCT03287479 (Gavi vs Cryotop)
- O-240 Automated oocyte vitrification with the DaVitri device, Human Reproduction (ESHRE 2025 abstracts)
- ClinicalTrials.gov NCT05607771 and NCT06853418 (DaVitri, Overture Life)
- Alpha Scientists in Reproductive Medicine, The Alpha consensus meeting on cryopreservation key performance indicators and benchmarks, RBMO, 2012
- Assisted Reproductive Technology (Regulation) Act, 2021, India Code
Your next step
Vendors of vitrification, cryo-storage or lab-automation systems can claim a free listing in our directory, so Indian lab managers can find you when they shortlist. Lab teams can browse the vendor discovery page and the workflow library.
General operational information only; not medical, clinical or legal advice. Product names are mentioned for information and are not endorsements. See our disclaimer.